Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0193112
DC FieldValue
dc.titleRevisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis
dc.contributor.authorRattanavipapong W.
dc.contributor.authorAnothaisintawee T.
dc.contributor.authorTeerawattananon Y.
dc.date.accessioned2020-03-27T01:05:18Z
dc.date.available2020-03-27T01:05:18Z
dc.date.issued2018
dc.identifier.citationRattanavipapong W., Anothaisintawee T., Teerawattananon Y. (2018). Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. PLoS ONE 13 (2) : e0193112. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0193112
dc.identifier.issn19326203
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/165968
dc.description.abstractThailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care’s benefit package. This study was conducted in respond to policy demand from the Thai government to assess the value for money and budget impact of introducing sofosbuvir-based regimens in the tax-based health insurance scheme. The Markov model was constructed to assess costs and benefits of the four treatment options that include: (i) current practice–peginterferon alfa (PEG) and ribavirin (RBV) for 24 weeks in genotype 3 and 48 weeks for other genotypes; (ii) Sofosbuvir plus peginterferon alfa and ribavirin (SOF+PEG-RBV) for 12 weeks; (iii) Sofosbuvir and daclatasvir (SOF+DCV) for 12 weeks; (iv) Sofosbuvir and ledipasvir (SOF+LDV) for 12 weeks for non-3 genotypes and SOF+PEG-RBV for 12 weeks for genotype 3 infection. Given that policy options (ii) and (iii) are for pan-genotypic infection, the cost of genotype testing was applied only for policy options (i) and (iv). Results reveal that all sofosbuvir-based regimens had greater quality adjusted life years (QALY) gains compared with the current treatment, therefore associated with lower lifetime costs and more favourable health outcomes. Additionally, among the three regimens of sofosbuvir, SOF+PEG-RBV for genotype 3 and SOF+LDV for non-3 genotype are the most cost-effective treatment option with the threshold of 160,000 THB per QALY gained. The results of this study had been used in policy discussion which resulted in the recent inclusion of SOF+PEG-RBV for genotype 3 and SOF+LDV for non-3 genotype in the Thailand’s benefit package. © 2018 Rattanavipapong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.publisherPublic Library of Science
dc.sourceUnpaywall 20200320
dc.subjectdaclatasvir
dc.subjectledipasvir
dc.subjectpeginterferon alpha
dc.subjectribavirin
dc.subjectsofosbuvir
dc.subjectantivirus agent
dc.subjectArticle
dc.subjectbudget
dc.subjectchronic hepatitis C
dc.subjectcontrolled study
dc.subjectcost benefit analysis
dc.subjectcost effectiveness analysis
dc.subjectcost utility analysis
dc.subjectdrug cost
dc.subjecteconomic evaluation
dc.subjecthealth care cost
dc.subjecthealth care policy
dc.subjecthealth insurance
dc.subjectHepatitis C virus genotype 3
dc.subjectMarkov chain
dc.subjectquality adjusted life year
dc.subjectquality of life
dc.subjecttax
dc.subjectThailand
dc.subjectbudget
dc.subjectchronic hepatitis C
dc.subjectcombination drug therapy
dc.subjectcost
dc.subjecteconomic model
dc.subjecteconomics
dc.subjectfemale
dc.subjectgenetics
dc.subjectgenotype
dc.subjectgenotyping technique
dc.subjecthuman
dc.subjectinsurance
dc.subjectmale
dc.subjectAntiviral Agents
dc.subjectBudgets
dc.subjectCosts and Cost Analysis
dc.subjectDrug Therapy, Combination
dc.subjectFemale
dc.subjectGenotype
dc.subjectGenotyping Techniques
dc.subjectHepatitis C, Chronic
dc.subjectHumans
dc.subjectMale
dc.subjectModels, Economic
dc.subjectUniversal Coverage
dc.typeArticle
dc.contributor.departmentSAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
dc.description.doi10.1371/journal.pone.0193112
dc.description.sourcetitlePLoS ONE
dc.description.volume13
dc.description.issue2
dc.description.pagee0193112
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0193112.pdf2.17 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.